I NTRO D U C TIO N
Vertigo
M E TH O DS
In order to detect a minimal difference of 1.5 points in the mean changes of VAS scores between the two treatment groups with a power of 90% and where p = 0.05 was considered significant, a sample size of 98 patients per group was required.
Estimation of the sample size was performed using NCSS Table I ). The VAS scores of the patients were labelled as: (a) 1st VAS score (before treatment); (b) 2nd VAS score (after treatment); and (c) 3rd VAS score (after any additional treatment). The differences between the 1st and 2nd VAS scores, and the 2nd and 3rd VAS scores were categorised as the 1st and 2nd VAS score differences, respectively. Comparing the 1st and 2nd VAS scores of each drug, a statistically significant difference between the two VAS scores was found (p < 0.001).
Both drugs were able to decrease the patients' 1st VAS and dizziness [n = 7, 7.0%]) (Fig. 1) . The risk for side effects was higher in patients treated with dimenhydrinate compared to those treated with piracetam (RR 1.219, 95% CI 1.018-1.459) ( Table V) .
D I SCU S S IO N
Vertigo is a symptom that is difficult to diagnose and treat, and its treatment can be either symptomatic or specific. periods. (5, 6) Females are affected twice as often as males in benign paroxysmal positional vertigo (BPPV). (7) Vertigo was also more frequently observed (61%-66%) in females in a number of previous reports. (8) (9) (10) Similarly, our study showed a higher incidence of vertigo in females (75.5%).
In the present study, when the 1st and 2nd VAS scores of the patients in both the dimenhydrinate and piracetam treatment groups were compared, a statistically significant difference was found between the two VAS scores for each drug (p < 0.001) (Table ll) . A significant decline in the VAS scores of the patients was found after treatment with either dimenhydrinate or piracetam. This finding not only demonstrates the effectiveness of both drugs in the treatment of vertigo, but also highlights the comparable effectiveness of both drugs (p < 0.001).
Piracetam is known to be effective in the treatment of vertigo of peripheral and central origin, (11, 12) Furthermore, piracetam decreases the frequency of episodes in patients with chronic recurrent vertigo. (13) All these effects of piracetam positively contribute to the development of chronic compensation.
The mean age of patients with vertigo in a study by Arya and Nunez (10) was 52.6 years, and in a larger series, the mean age of patients with BPPV was reported to be 50 years. (14, 15) In our study, the mean age of our patients was 45 years, with vertigo observed mostly in the fifth decade of life (24%). In the piracetam treatment group, the 1st VAS score differences of the subgroups of patients below and over 40 years of age were comparable (p = 0.189). Therefore, piracetam was deemed to (4) In line with this finding, the most frequent side effect in our study was drowsiness. It is mentioned in the literature that side effects such as depression (rare, less than 2%), nervousness, somnolence, hyperkinesia and tremor can be observed after piracetam treatment. (13) However, based on our results, drowsiness was detected in only 15% of our patients who were treated with piracetam.
One of the limitations of our study was that the length of stay in the emergency department, based on side effects of the drugs and their influence on discharge decision, were not recorded.
However, our study found that dimenhydrinate and piracetam have similar levels of effectiveness in the treatment of acute vertigo. We thus conclude that piracetam could be more frequently used in the treatment of acute vertigo in the emergency department, as it has fewer side effects and better vestibular compensation than dimenhydrinate, and is effective in both acute and chronic vertigo. 
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